A major new study shows that the antiplatelet drug prasugrel offers similar protection against serious heart problems as ticagrelor, but with a key advantage: significantly less bleeding. The SWITCH SWEDEHEART trial, involving over 17,000 acute coronary syndrome patients who underwent stent placement, presented its findings on August 29, 2026, at the ESC Congress 2026 in Munich, Germany, and simultaneously published them in the New England Journal of Medicine.[escardio+2]
New Standard for Heart Patients
The trial found that a treatment strategy using prasugrel resulted in comparable rates of major cardiovascular events, such as death, heart attack, or stroke, when compared to a ticagrelor-based approach. The primary endpoint, a combination of death from any cause, myocardial infarction, or stroke, occurred in 11.1% of patients under the prasugrel policy and 11.8% under the ticagrelor policy over one year.This difference was not statistically significant.[escardio+3]
However, the risk of major bleeding at one year was notably lower for patients receiving prasugrel. Just 4.2% of patients in the prasugrel group experienced major bleeding, compared to 4.4% in the ticagrelor group.This represents a significant reduction in a serious complication for heart patients.[escardio+4]
Professor Elmir Omerovic, the principal investigator from Sahlgrenska University Hospital in Gothenburg, Sweden, highlighted the trial’s importance. He stated that prasugrel offered similar protection against major cardiovascular events, but with a clear signal toward less bleeding and lower cost. This combination is a potentially important factor for both patients and healthcare systems.[escardio+1]
Real-World Evidence
The SWITCH SWEDEHEART trial used a unique "stepped-wedge" design, randomizing healthcare regions rather than individual patients across Sweden. Seven Swedish regions, divided into three clusters, gradually switched their default P2Y12 inhibitor from ticagrelor to prasugrel at different, randomly assigned times between 2021 and 2024. This pragmatic approach allowed researchers to study the drugs' effects in a real-world setting, including patients often excluded from traditional clinical trials.[escardio+3]
The study included 17,095 consecutive adult patients with acute coronary syndromes who underwent percutaneous coronary intervention (PCI), a procedure to open blocked arteries. This broad inclusion meant the trial evaluated the drugs in a diverse group of patients, including elderly individuals and those with prior strokes or who were already taking oral anticoagulants.[escardio+3]
Professor Omerovic praised the novel method, noting that it allowed a large, policy-level randomized trial to be conducted within a national registry. He added that this was achieved at a fraction of the cost of a conventional trial, providing valuable insights into the real-world impact of treatments.[escardio+1]
Impact on Treatment Guidelines
Potent P2Y12 inhibitors, like prasugrel and ticagrelor, are vital medications combined with aspirin to prevent serious cardiovascular events in patients with acute coronary syndromes after coronary stenting. The debate over which of these two potent inhibitors holds an advantage has been ongoing.[escardio]
Previous research, such as the ISAR-REACT 5 trial in 2020, also suggested a prasugrel-based strategy was superior for major cardiovascular events without increasing bleeding. However, questions remained about whether those findings would apply to a broader, unselected patient population in everyday clinical practice. The SWITCH SWEDEHEART trial now provides that crucial real-world evidence.[escardio+6]
The 2023 European Society of Cardiology (ESC) Guidelines already suggested considering prasugrel over ticagrelor for ACS patients undergoing PCI. The results from SWITCH SWEDEHEART strongly support and refine this recommendation. The ability to reduce the prasugrel dose as needed might contribute to the observed lower bleeding rates.[escardio+3]
This study’s findings suggest that healthcare systems can prioritize prasugrel as a default treatment option for these patients. The reduced bleeding risk, combined with similar efficacy and potential cost savings, offers a compelling argument for its use.[tctmd]
